Precision medicine in AMD: SPAC merger sees Gemini make its public debut
Gemini Therapeutics and Foresite Capital's SPAC FSDC have merged and become a combined public company that will develop precision medicines…
ByFocus box
How a sleeping drug awakened a patient with akinetic mutism
Akinetic mutism is a rare disorder of diminished motivation where patients are awake, but in state of profound apathy, making…
By
Half of top 20 Bio/Pharma companies by market cap show growth in Q4 2020 due to Covid-19 pandemic
The final quarter of 2020 saw slight growth in the overall market performances of the top 20 global Bio/Pharma companies…
By
Immortal cells and informed consent: the legacy of Henrietta Lacks
The ‘HeLa’ cell line has been a mainstay of the biotechnology industry for decades, propagated from the biopsy of a…
By
Q&A with SVB’s Nooman Haque: what does 2021 have in store for healthcare investment?
SVB’s annual report found that 2020 was a successful year for healthcare fundraising and investment with neurology leading the way.…
By
Q&A with Goodwin’s Andrew Harrow: exploring the pharma deals outlook in 2021
Despite the pandemic, 2020 was a productive year for the pharma industry in terms of investment and deals. Goodwin partner…
By
Timeline: charting the choppy history of ‘magic bullet’ antibody-drug conjugates
Antibody-drug conjugates (ADCs) allow for targeted delivery of chemotherapy to tumours, therefore reducing horrible, off-target side effects for patients. Until…
By
EU/AZ Covid-19 vaccine row: what’s the exit strategy?
For the past week, the EU and AZ have been embroiled in a dispute around supply of the company’s vaccine…
By